Leukemia fusion proteins and co-repressor complexes: Changing paradigms

Journal of Cellular Biochemistry

Volumn 94, Issue 5, 2005, Pages 864-869

  Redner, Robert L ^a,c   Liu, Johnson M ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Hillman Cancer Center Research Pavilion   (United States)

Author keywords

Acute myeloid leukemia; AML ETO; Co repressors; HDAC; N COR; PML RAR; SMRT

Indexed keywords

DNA BINDING PROTEIN; HYBRID PROTEIN; REGULATOR PROTEIN; REPRESSOR PROTEIN; HISTONE DEACETYLASE;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER INHIBITION; CHROMOSOME TRANSLOCATION; COMPLEX FORMATION; GENE EXPRESSION; GENE TARGETING; HUMAN; LEUKEMOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; REVIEW; DRUG ANTAGONISM; LEUKEMIA; METABOLISM;

HISTONE DEACETYLASES; HUMANS; LEUKEMIA; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS;

EID: 23744480886     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20368     Document Type: Review

References (43)

1. Alland L, Muhle R, Hou H, Jr., Potes J, Chin L, Schreiber-Agus N, DePinho RA. 1997. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 387:49-55.
2. Arai Y, Kyo T, Miwa H, Arai K, Kamada N, Kita K, Ohki M. 2000. Heterogenous fusion transcripts involving the NUP98 gene and HOXD13 gene activation in a case of acute myeloid leukemia with the t(2;11)(q31;p15) translocation. Leukemia 14:1621-1629.
3. Borrow J, Shearman AM, Stanton VP, Jr., Becher R, Collins T, Williams AJ, Dube I, Katz F, Kwong YL, Morris C, Ohyashiki K, Toyama K, Rowley J, Housman DE. 1996. The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9. Nat Genet 12:159-167.
4. Chen JD, Evans RM. 1995. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377:454-457.
5. Cuenco GM, Nucifora G, Ren R. 2000. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: A model for human AML. Proc Natl Acad Sci USA 97:1760-1765.
6. de Guzman CG, Warren AJ, Zhang Z, Gartland L, Erickson P, Drabkin H, Hiebert SW, Klug CA. 2002. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol 22:5506-5517.
7. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, Fuks F, Lo Coco F, Kouzarides T, Nervi C, Minucci S, Pelicci PG. 2002. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295:1079-1082.
8. Doucas V, Brockes JP, Yaniv M, de The H, Dejean A. 1993. The PML-retinoic acid receptor alpha translocation converts the receptor from an inhibitor to a retinoic acid-dependent activator of transcription factor AP-1. Proc Natl Acad Sci USA 90:9345-9349.
9. Duprez E, Wagner K, Koch H, Tenen DG. 2003. C/EBPbeta: A major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells. Embo J 22:5806-5816.
10. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. 1998. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 18:7185-7191.
11. Gu BW, Wang Q, Wang JM, Xue YQ, Fang J, Wong KF, Chen B, Shi ZZ, Shi JY, Bai XT, Wu DH, Chen Z, Chen SJ. 2003. Major form of NUP98/HOXC11 fusion in adult AML with t(11;12)(p15;q13) translocation exhibits aberrant trans-regulatory activity. Leukemia 17:1858-1864.
12. Guidez F, Ivins S, Zhu J, Soderstrom M, Waxman S, Zelent A. 1998. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to pml- and plzf-rar-alpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 91:2634-2642.
13. Hauksdottir H, Privalsky ML. 2001. DNA recognition by the aberrant retinoic acid receptors implicated in human acute promyelocytic leukemia. Cell Growth Differ 12:85-98.
14. He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, Pandolfi PP. 1998. Distinct interactions of pml-rar-alpha and plzf-rar-alpha with co-repressors determine differential responses to ra in apl. Nature Genetics 18:126-135.
15. Heinzel T, Lavinsky RM, Mullen TM, Soderstrom M, Laherty CD, Torchia J, Yang WM, Brard G, Ngo SD, Davie JR, Seto E, Eisenman RN, Rose DW, Glass CK, Rosenfeld MG. 1997. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387:43-48.
16. Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Soderstrom M, Glass CK. 1995. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377:397-404.
17. Izutsu K, Kurokawa M, Imai Y, Ichikawa M, Asai T, Maki K, Mitani K, Hirai H. 2002. The t(3;21) fusion product, AML1/Evi-1 blocks AML1-induced transactivation by recruiting CtBP. Oncogene 21:2695-2703.
18. Jepsen K, Hermanson O, Onami TM, Gleiberman AS, Lunyak V, McEvilly RJ, Kurokawa R, Kumar V, Liu F, Seto E, Hedrick SM, Mandel G, Glass CK, Rose DW, Rosenfeld MG. 2000. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 102:753-763.
19. Kwong YL, Pang A. 1999. Low frequency of rearrangements of the homeobox gene HOXA9/t(7;11) in adult acute myeloid leukemia. Genes Chromosomes Cancer 25:70-74.
20. Laherty CD, Yang WM, Sun JM, Davie JR, Seto E, Eisenman RN. 1997. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 89:349-356.
21. Lenny N, Westendorf JJ, Hiebert SW. 1997. Transcriptional regulation during myelopoiesis. Mol Biol Rep 24:157-168.
22. Lin RJ, Evans RM. 2000. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell 5:821-830.
23. Look AT. 1997. Oncogenic transcription factors in the human acute leukemias. Science 278:1059-1064.
24. Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, Huynh KD, Bardwell VJ, Lavinsky RM, Rosenfeld MG, Glass C, Seto E, Hiebert SW. 1998. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 18:7176-7184.
25. Lutterbach B, Westendorf JJ, Linggi B, Isaac S, Seto E, Hiebert SW. 2000. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J Biol Chem 275:651-656.
26. Melnick A, Licht JD. 1999. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93:3167-31215.
27. Perissi V, Staszewski LM, Mclnerney EM, Kurokawa R, Krones A, Rose DW, Lambert MH, Milburn MV, Glass CK, Rosenfeld MG. 1999. Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev 13:3198-3208.
28. Pineault N, Buske C, Feuring-Buske M, Abramovich C, Rosten P, Hogge DE, Aplan PD, Humphries RK. 2003. Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1. Blood 101:4529-4538.
29. Pineault N, Abramovich C, Ohta H, Humphries RK. 2004. Differential and common leukemogenic potentials of multiple NUP98-Hox fusion proteins alone or with Meis1. Mol Cell Biol 24:1907-1917.
30. Pollock JL, Westervelt P, Walter MJ, Lane AA, Ley TJ. 2001. Mouse models of acute promyelocytic leukemia. Curr Opin Hematol 8:206-211.
31. Privalsky ML. 2004. The role of corepressors in transcriptional regulation by nuclear hormone receptors. Annu Rev Physiol 66:315-360.
32. Raza-Egilmez SZ, Jani-Sait SN, Grossi M, Higgins MJ, Shows TB, Aplan PD. 1998. NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia. Cancer Res 58:4269-4273.
33. Redner RL, Wang J, Liu JM. 1999. Chromatin remodeling and leukemia: New therapeutic paradigms. Blood 94:417-428.
34. Salomoni P, Pandolfi PP. 2002. The role of PML in tumor suppression. Cell 108:165-170.
35. Sanz MA, Martin G, Rayon C, Esteve J, Gonzalez M, Diaz-Mediavilla J, Bolufer P, Barragan E, Terol MJ, Gonzalez JD, Colomer D, Chillon C, Rivas C, Gomez T, Ribera JM, Bornstein R, Roman J, Calasanz MJ, Arias J, Alvarez C, Ramos F, Deben G. 1999. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 94:3015-3021.
36. Sitterlin D, Tiollais P, Transy C. 1997. The RAR alpha-PLZF chimera associated with Acute Promyelocytic Leukemia has retained a sequence-specific DNA-binding domain. Oncogene 14:1067-1074.
37. Tanaka T, Mitani K, Kurokawa M, Ogawa S, Tanaka K, Nishida J, Yazaki Y, Shibata Y, Hirai H. 1995. Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias. Mol Cell Biol 15:2383-2392.
38. Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG, Hiddemann W, Behre G. 2003. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood 101:270-277.
39. Vermeulen M, Carrozza MJ, Lasonder E, Workman JL, Logie C, Stunnenberg HG. 2004. In vitro targeting reveals intrinsic histone tail specificity of the Sin3/histone deacetylase and N-CoR/SMRT corepressor complexes. Mol Cell Biol 24:2364-2372.
40. Wang JX, Hoshino T, Redner RL, Kajigaya S, Liu JM. 1998. Eto, fusion partner in t(8-21) acute myeloid leukemia, represses transcription by interaction with the human ncor/msin3/ridac1 complex. Proceedings of the National Academy of Sciences of the United States of America 95:10860-10865.
41. Wang J, Saunthararajah Y, Redner RL, Liu JM. 1999. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res 59:2766-2769.
42. Warrell RP, He LZ, Richon V, Calleja E, Pandolfi PP. 1998. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. Journal of the National Cancer Institute 90:1621-1625.
43. Zhang J, Kalkum M, Yamamura S, Chait BT, Roeder RG. 2004. E protein silencing by the leukemogenic AML1-ETO fusion protein. Science 305:1286-1289.